Research programme: CAR-T cell therapeutics - BioAtla/F1 Oncology

Alternative Names: CAB CAR-T therapy

Latest Information Update: 11 Jan 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator BioAtla
Developer BioAtla; F1 Oncology
Class CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

08 Jan 2018 Preclinical trials in Solid tumours in USA prior to January 2018 (Parenteral)
06 Jan 2017 Early research in Solid tumours in USA (Parenteral)
06 Jan 2017 F1 Oncology plans clinical trial for Solid tumours

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.